LGD-3303

The company Ligand Pharmaceuticals originally developed the parent compound LGD-4033. In 2007 they synthesized a derivative called 9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[3,2-f]quinoline-7(6H)-one, better known as LGD-3303. This SARM, which is commercially available, is an orally taken, nonsteroidal compound. Early studies in animal models have shown that it can increase bone mineral density (BMD) and muscle mass. Due to its high bioavailability and reported effectiveness, LGD-3303 is currently being investigated for its ability to prevent muscle wasting and osteoporosis.

Main research results for LGD-3303

1. Increases muscle mass without adversely affecting prostate weight in orchiectomized male Sprague-Dawley rats.

2. Increases both bone mineral content (BMC) and BMD in female Sprague-Dawley rats after ovariectomy.

Methodology

Experiment 1: Male Rats

Male Sprague-Dawley rats, 7-8 weeks old, each weighing about 200 grams, were purchased from Harlan for experimental testing. After a 14-day recovery period, the rats were treated with varying doses of LGD-3303 or testosterone propionate. After two weeks, the rats were euthanized to allow for further analyses.

Experiment 2: Female Rats

Female Sprague-Dawley rats, approximately 3 months old and weighing 175-200 grams, were also purchased from Harlan. After a recovery period of 7 weeks, the rats were divided into different treatment groups and treated for 12 weeks.

Discussion

1. The study found that both LGD-3303 and testosterone propionate were able to increase anabolic activity in orchiectomized male rats. However, unlike testosterone, LGD-3303 increased muscle weight without significantly increasing prostate weight.

2. In the female rats, treatment with LGD-3303 led to a significant increase in both bone mineral content and bone mineral density. This suggests that LGD-3303 has effective anabolic activity on bone.

The biomechanical tests confirmed that all three treatment groups showed improvements, but the combination treatment was most successful, although not significantly more than treatment with LGD-3303 alone.

CONCENTRATION
10 mg / ml.

DISCLAIMER
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or household use. Familiarize yourself with our DISCLAIMER before ordering.

LGD3303 - Oplossing, 300 mg (10 mg / ml)